KASL clinical practice guidelines: management of hepatitis C.

KASL clinical practice guidelines: management of hepatitis C.

Item
http://www.wikidata.org/entity/Q51836024
Prediction of the Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Patients after Sustained Virological Response by Aspartate Aminotransferase to Platelet Ratio Index.Comparison of clinical manifestations and outcomes between hepatitis B virus- and hepatitis C virus-related hepatocellular carcinoma: analysis of a nationwide cohortHepatitis C virus infection in patients with hemophilia in Korea: Is antiviral therapy effective and safe?Hepatitis C and not Hepatitis B virus is a risk factor for anti-tuberculosis drug induced liver injuryEstimating the Cost-Effectiveness of One-Time Screening and Treatment for Hepatitis C in Korea.Incidence of and risk factors for thyroid dysfunction during peginterferon α and ribavirin treatment in patients with chronic hepatitis CRelationship between 25-Hydroxyvitamin D Levels and Liver Fibrosis as Assessed by Transient Elastography in Patients with Chronic Liver Disease.The clinical outcomes of chronic hepatitis C in South Korea: A prospective, multicenter cohort study.Clinical features of hepatitis B and C virus infections, with high α-fetoprotein levels but not hepatocellular carcinoma.Daclatasvir/Asunaprevir/Beclabuvir (DCV-TRIO), All-Oral, Fixed-Dose Combination for Patients With Chronic HCV Genotype 1.Historical epidemiology of hepatitis C virus (HCV) in select countries - volume 3.A phase IIIb study of ledipasvir/sofosbuvir fixed-dose combination tablet in treatment-naïve and treatment-experienced Korean patients chronically infected with genotype 1 hepatitis C virus.A phase 3b study of sofosbuvir plus ribavirin in treatment-naive and treatment-experienced Korean patients chronically infected with genotype 2 hepatitis C virus.Clinical Utility of a New Automated Hepatitis C Virus Core Antigen Assay for Prediction of Treatment Response in Patients with Chronic Hepatitis C.Real-life prevalence of resistance-associated variants against non-structural protein 5A inhibitors and efficiency of Daclatasvir + Asunaprevir therapy in Korean patients with genotype 1b hepatitis CDaclatasvir Plus Asunaprevir for the Treatment of Patients with Hepatitis C Virus Genotype 1b Infection: Real-World Efficacy, Changes in Liver Stiffness and Fibrosis Markers, and Safety.Recent update of the 2017 Korean Association for the Study of the Liver (KASL) treatment guidelines of chronic hepatitis C: comparison of guidelines from other continents, 2017 AASLD/IDSA and 2016 EASL.
P2860

KASL clinical practice guidelines: management of hepatitis C.

Item
http://www.wikidata.org/entity/Q51836024
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
KASL clinical practice guidelines: management of hepatitis C.
@en
KASL clinical practice guidelines: management of hepatitis C.
@nl
type
label
KASL clinical practice guidelines: management of hepatitis C.
@en
KASL clinical practice guidelines: management of hepatitis C.
@nl
prefLabel
KASL clinical practice guidelines: management of hepatitis C.
@en
KASL clinical practice guidelines: management of hepatitis C.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P577
P698
P932
P356
P1433
P1476
KASL clinical practice guidelines: management of hepatitis C.
@en
P2093
Korean Association for the Study of the Liver (KASL)
P2860
P304
P31
P356
P433
P478
P577
P698
P932